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TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS 
GENERATED BY MYCN AND P53 DEFECTS IN VENTRICULAR 
ZONE PROGENITORS.
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Medulloblastoma (MB) represents the most common embryonal tumour 
of the Central Nervous System in childhood. MB occurs in the cerebellum 
and molecular features dictate the classification into four subgroups. Al-
though Group3 (Gr3) MB tumours are dominated by primitive progenitor-
like cells, the cells of origin remain unidentified. Gr3 MB is associated with 
relatively common MYC family member amplification and overexpression, 
often combined with p53 pathway defects at relapse. Molecularly stratified 
treatment is not yet available, causing Gr3 MB and its subsequent relapse 
to often represent an unstoppable progressive disease. The limited under-
standing of Gr3 tumorigenesis and targeted therapy development is also due 
to the lack of faithful in vivo models and consequently, their use in preclin-
ical studies. We have now developed a new germline genetically engineered 
mouse model (GEMM), harbouring MYCN amplification in a p53 inactive 
background (tamoxifen-inducible p53 activation, Trp53ERTAM). The pur-
pose of the GEMM is to investigate the developmental significance of MYC 
aberration in putative Gr3 MB cells of origin and exploit it in preclinical 
studies. A LSL-MYCN-Luciferase strain was crossed with mice expressing 
Cre recombinase under the Blbp promoter and subsequently to Trp53ERTAM 
inducible mice. As result, the MYCN overexpression alone did not generate 
tumours, conversely to the combination of MYCN with p53 deregulation. 
Tumours arise exclusively in the hindbrain of homozygote mice, with a pene-
trance of 100% and a latency of ~135 days. Pathology report suggests tu-
mours are Gr3 MB with large cell/anaplastic (LCA) histology. Preliminary 
transcriptional profiling data analysis reveals that tumours share molecular 
features with human counterparts, clustering with Gr3 MB. Ongoing ana-
lysis will explore the tumour cells of origin, followed by tumour progression 
alteration restoring p53 activity and blood-brain barrier integrity status. 
In conclusion, we have developed a MYCN/Trp53ERTAM Gr3 MB GEMM 
arising from ventricular zone progenitor cells and resembling human cancer 
characteristics.
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Introduction: Image-based phenotypic drug profiling is receiving 
increasing attention in drug discovery and precision medicine. Compared 
to classical end-point measurements quantifying drug response, image-based 
profiling enables both the quantification of drug response and characteriza-
tion of disease entities and drug mechanisms of actions. In pediatric preci-
sion oncology, we aim to study drug response in patient-derived 3D spheroid 
tumor cell cultures and tackle the challenges of a lack of image-segmentation 
methods and limited patient-derived material.  Methods: We investigate 
deep transfer learning with patient-by-patient fine-tuning for cell-viability 
quantification. We fine-tune a convolutional neural network (pre-trained on 
ImageNet) with many cell-line-specific and few patient-specific assay con-
trols. The method is validated using 3D cell cultures in 384-well microplates 
derived from cell lines with known drug sensitivities and tested with pri-
mary patient-derived samples. Network outputs at different drug concentra-
tions are used for drug-sensitivity scoring; dense-layer activations are used 
in t-distributed stochastic neighbor embedding and clustering of drugs. Re-
sults: Cell-line experiments confirm expected hits, such as effective treat-
ment with BRAF inhibitors in a BRAF V600E mutated brain tumor model 
and NTRK inhibitors in a cell line harboring an NTRK-fusion, indicating 
the predictive power of deep learning to identify drug-hit candidates for 
individual patients. In patient-derived samples, clustering of drugs further 
confirms phenotypic similarity according to their mechanisms of actions. 
Combining drug scoring with phenotypic clustering may provide opportun-
ities for complementary combination treatments. Conclusion: Deep transfer 
learning with patient-by-patient fine-tuning is a promising, segmentation-
free image-analysis approach for precision medicine and drug discovery 
based on 3D spheroid cell cultures.
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Background: Development of in vitro models of pediatric brain tumors 
(pBT) is instrumental for both understanding the contributing oncogenic 
molecular mechanisms and identifying and testing new therapeutic strat-
egies. Primary cell lines should be established and managed to prevent epi-
genetic and genetic alterations and thus recapitulating the original tumor. 
DNA methylation (DM) is a stable epigenetic modification, altered in 
cancer and recently used to classify tumors. We aim to apply DM and Copy 
Number Variation (CNV) profiling to characterize pBT primary cell lines 
and tumors. Methods: We investigated 34 pBT tissues from different hist-
ology paired to 52 their derived primary cultures in both 2D and 3D con-
ditions, as stem-cells or in serum-supplemented medium, and both short 
and long-terms in culture. We studied 18 additional pBT-derived cell-lines, 
9 organoids, 5 commercial cell-lines, and 122 pBT tissues from the same 
histological categories, as controls, for a total of 240 genome-wide DM pro-
files. We analyzed DM and CNV profiles by using Illumina EPIC-arrays. By 
means of a bump hunting strategy, we identified differentially methylated 
regions in faithful vs unfaithful cell lines, and performed a functional char-
acterization using over-representation analysis. Results The 69% (25/36) of 
cells at early passages retained genetic alteration and the same DM patterns 
of the original tumors, with no differences related to 2D/3D methods or 
the presence of serum in media. The 70% (24/34) of primary cell lines ana-
lyzed at later passages (>5 or >14 days in culture) diverged from the primary 
tumor, the totality of those cultured with serum. All divergent cells clus-
tered together acquiring common deregulated epigenetic signature induced 
by serum culture media, 2D methods and longer time in culture. Conclu-
sions: We have shown that global DM profiles, along with CNV analysis 
are useful tools to detect the recapitulation of pBT-derived primary cell-lines 
from the original tumor. Whatever subgroups tested, our results suggest that 
in vitro models should be passaged as little as possible to retain the epigen-
etic and genetic alterations of the tumors and thus to be considered relevant 
for basic and translational biology. 
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To determine the role of microRNA regulation in brain tumor develop-
ment, we incorporated a conditional allele of the microRNA processing 
enzyme Dicer to a previously characterized glioma mouse model based 
on inactivation of the tumor suppressors Nf1, Trp53, and Pten using the 
Nestin-creERT2 transgene. Loss of Dicer and tumor suppressors at adult 
ages led to glioma development; however, mutant mice tamoxifen induced 
at early postnatal ages developed medulloblastoma instead of glioma. The 
switch in tumor spectrum occurred with 100% penetrance and tumors were 
histologically indistinguishable from human medulloblastoma (MB). The 
minimum genetic mutations required for MB formation were Dicer and 
Trp53. Nf1 was dispensable, while additional loss of Pten produced more 
invasive tumors and leptomeningeal metastases. The time window for ini-
tiation of tumorigenesis was until the 2nd postnatal week, coinciding with 
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